Straits Times Index
3,140.75 -42.86 (-1.35%) Nikkei
38,471.20 -761.60 (-1.94%) Hang Seng
16,233.49 -366.97 (-2.21%) FTSE 100
7,859.24 -106.29 (-1.33%) Bitcoin USD
63,373.27 -3,073.88 (-4.63%) CMC Crypto 200
885.54 0.00 (0.00%)
VRTX Jan 2025 290.000 put
- Associated Press Finance
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers
For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone. Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country’s ongoing drug epidemic. Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain.
- Zacks
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Zacks
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
